Max T W Dufford

age ~61

from Salt Lake City, UT

Get Report

Also known as:

Max T Dufford
Max Taylor Dufford
Max Taylor Wil Dufford
Max Taylor William Dufford
Max W Dufford
Max T William
Max Singh
Dufford Max Tw

Phone and address:: 1145 1500, Salt Lake City, UT 84105
8015835897

Connected to:

Max Dufford Phones & Addresses

1145 1500, Salt Lake Cty, UT 84105 • 8015835897
1468 Logan Ave, Salt Lake City, UT 84105 • 8015835897
Spokane Valley, WA
Seattle, WA

Work

Company:

Myrexis inc - Salt Lake City, UT
2009
Position:

Scientist ii

Education

School / High School:

University of Washington- Seattle, WA
1988
Specialities:

BS in Molecular and Cellular Biology

Resumes

Max Dufford Salt Lake City, UT

view source

Work:

Myrexis Inc
Salt Lake City, UT
2009 to 2011
Scientist II Myriad Genetics Inc
Salt Lake City, UT
1998 to 2008
Bioinformatics Programmer III Aeiveos Sciences Group
Seattle, WA
1995 to 1997
Scientific Programmer Fred Hutchinson Cancer Research Center
Seattle, WA
1992 to 1995
Research Associate

Education:

University of Washington
Seattle, WA
1988
BS in Molecular and Cellular Biology

Us Patents

Nucleic Acid Encoding A Phosphatase 2C That Interacts With Fe 65
view source
US Patent:

6653102, Nov 25, 2003
Filed:

Oct 11, 2001
Appl. No.:

09/973963
Inventors:

Jean-Marc Roch - Salt Lake City UT
Paul L. Bartel - Salt Lake City UT
Karen Heichman - Salt Lake City UT
Kimberly Mauck - Sandy UT
Max Dufford - Salt Lake City UT
Assignee:

Myriad Genetics, Inc. - Salt Lake City UT
International Classification:

C12N 1500
US Classification:

435 691, 4353201, 435325, 4352523, 43525411, 4352542, 435183, 536 235
Abstract:

The present invention relates to the discovery of proteinâprotein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimers disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.